✦ LIBER ✦

Phase II Study of Gemcitabine and Bevacizumab As First-Line Treatment in Taxane-Pretreated, HER2-Negative, Locally Recurrent or Metastatic Breast Cancer

✍ Scribed by Rachel Borson; Graydon Harker; James Reeves; Thaddeus Beck; Steven Hager; William Horvath; Michael Jones; Guy Tillinghast; Edward Arrowsmith; Grant Harrer; Fred J. Kudrik; Stephen C. Malamud; Jane Bromund; Haoyue Zeigler; Datchen Fritz Tai; Lori J. Kornberg; Coleman Obasaju; Mauro Orlando; Denise A. Yardley

Book ID: 118430402
Publisher: CIG Media Group, LP.
Year: 2012
Tongue: English
Weight: 387 KB
Volume: 12
Category: Article
ISSN: 1526-8209
DOI: 10.1016/j.clbc.2012.07.004

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

First-line therapy with gemcitabine and

First-line therapy with gemcitabine and paclitaxel in locally, recurrent or metastatic breast cancer: A phase II study

✍ Djelila Allouache; Sulochana R Gawande; Michele Tubiana-Hulin; Nicole Tubiana-Ma 📂 Article 📅 2005 🏛 BioMed Central 🌐 English ⚖ 275 KB

Final results of a phase II study ofnab-

Final results of a phase II study ofnab-paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer

✍ Christopher Lobo; Gilberto Lopes; Odalys Baez; Aurelio Castrellon; Annapoorna Fe 📂 Article 📅 2010 🏛 Springer US 🌐 English ⚖ 268 KB

Gemcitabine as prolonged infusion and vi

Gemcitabine as prolonged infusion and vinorelbine in anthracycline and/or taxane pretreated metastatic breast cancer: a phase II study

✍ Peter Schmid; Volker Heilmann; Carsten-Oliver Schulz; Annette Dieing; Silvia Leh 📂 Article 📅 2005 🏛 Springer-Verlag 🌐 English ⚖ 205 KB

Phase II Trial of Weekly Docetaxel/Gemci

Phase II Trial of Weekly Docetaxel/Gemcitabine as First-Line Chemotherapy in Patients with Locally Recurrent or Metastatic Breast Cancer

✍ Joyce A. O'Shaughnessy; Robert Pluenneke; Jack Sternberg; Pankaj Khandelwal; Des 📂 Article 📅 2006 🏛 CIG Media Group, LP. 🌐 English ⚖ 482 KB

Motesanib, or open-label bevacizumab, in

Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study

✍ Miguel Martin; Henri Roche; Tamas Pinter; John Crown; M John Kennedy; Louise Pro 📂 Article 📅 2011 🏛 The Lancet 🌐 English ⚖ 230 KB

455 A phase II study of first-line combi

455 A phase II study of first-line combination chemotherapy with docetaxel and gemcitabine in anthracycline-pretreated, Her-2 negative metastatic breast cancer (MBC)

✍ F. Lenz; F. Beldermann; M. Geberth; G. Bastert; A. Schneeweiss 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 164 KB